131513-35-4

Usage

Uses

Used in Pharmaceutical Industry:
3,4-Dihydro-3-[(4-morpholinyl)methyl]-2H-1,4-benzoxazine is used as a potential antipsychotic agent for the treatment of various mental disorders. Its pharmacological properties may help in managing symptoms associated with psychosis and related conditions.
Used in Central Nervous System Depressant Applications:
3,4-Dihydro-3-[(4-morpholinyl)methyl]-2H-1,4-benzoxazine is used as a potential central nervous system depressant, which may help in reducing anxiety, agitation, and other symptoms related to overstimulation of the nervous system.

InChI:InChI=1/C13H18N2O2/c1-2-4-13-12(3-1)14-11(10-17-13)9-15-5-7-16-8-6-15/h1-4,11,14H,5-10H2

Upstream product

• 131513-32-1 1-Morpholin-4-yl-3-(2-nitro-phenoxy)-propan-2-ol 
• 131513-33-2 3-(4-morpholinyl)-1-(2-nitrophenoxy)-2-propanone 

Downstream Products

• 131513-18-3 WIN 55,212-2 
• 131513-25-2 3-(4-Morpholinylmethyl)-5-methyl-6-(2-fluorobenzoyl)-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine 
• 131513-30-9 (R)-(+)-<2,3-dihydro-5-methyl-3-<(4-morpholinyl)methyl>pyrrolo<1,2,3-de>-1,4-benzoxazin-6-yl>(4-methoxyphenyl)methanone 
• 131513-29-6 (S)-(-)-<2,3-dihydro-5-methyl-3-<(4-morpholinyl)methyl>pyrrolo<1,2,3-de>-1,4-benzoxazin-6-yl>(4-methoxyphenyl)methanone 
• 131513-17-2 3-(4-morpholinylmethyl)-5-methyl-6-(4-methoxybenzoyl)-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine 
• 137795-09-6 3-(4-morpholinylmethyl)-5-ethyl-6-(4-methoxybenzoyl)-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine 
• 137794-94-6 3-(4-morpholinylmethyl)-6-(4-methoxybenzoyl)-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine 
• 131513-55-8 (+)-3-(4-morpholinylmethyl)-5-methyl-6-phenylthio-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine 

Relevant academic research and scientific papers

Conformationally restrained analogues of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor

Pravadoline (1) is an (aminoalkyl)indole analgesic agent which is an inhibitor of cyclooxygenase and, in contrast to other NSAIDs, inhibits neuronally stimulated contractions in mouse vas deferens (MVD) preparations (IC50 = 0.45 μM). A number of conformationally restrained heterocyclic analogues of pravadoline were synthesized in which the morpholinoethyl side chain was tethered to the indole nucleus. Restraining the morpholine diminished the ability of these pravadoline analogues to inhibit prostaglandin synthesis in vitro. In contrast, mouse vas deferens inhibitory activity was enhanced in [2,3-dihydro-5-methyl-3-[(4- morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-(4- methoxyphenyl)methanone (20). Only the R enantiomer of 20 was active (IC50 = 0.044 μM). An optimal orientation of the morpholine nitrogen for MVD inhibitory activity within the analogues studied was in the lower right quadrant, below the plane defined by the indole ring. A subseries of analogues of 20 and a radioligand of the most potent analogue, (R)-(+)-(2,3- hydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6- yl](1-naphthalenyl)methanone (21) were prepared. Inhibition of radioligand binding in rat cerebellar membranes was observed to correlate with functional activity in mouse vas deferens preparations. Binding studies with this ligand (Win 55212-2) have helped demonstrate that the (aminoalkyl)indole binding site is functionally equivalent with the CP-55,940 cannabinoid binding site. These compounds represent a new class of cannabinoid receptor agonists.